Short answer
TriSalus Life Sciences, Inc. (TLSI) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $12M (up 57.4% year over year) with net income of −$11M.
Q3 2025 key financials · XBRL
- Revenue
- $12M
- +57.4% YoY · +3.1% QoQ
- Net income
- −$11M
- −353.1% YoY · −30.4% QoQ
- Operating margin
- -77.9%
- Gross margin
- 83.5%
- EPS (diluted)
- −$1.07
- −970.0% YoY · −311.5% QoQ
Source: XBRL data from the TriSalus Life Sciences, Inc. (TLSI) Q3 2025 10-Q on SEC EDGAR. USD.
TriSalus Life Sciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11.566M, up 57.4% YoY from $7.349M, driven by higher TriNav units sold
- Gross margin 83.5% vs 86.3% YoY, with newly launched products lowering manufacturing efficiency
- TriNav strongest product line, driving quarterly revenue growth; revenue $11.566M
- Cash and equivalents $22.7M at September 30, 2025; operating cash use $15.528M for nine months
- $22.0M private placement and $10.0M delayed-draw loan; management expects continued net losses and potential additional capital needs
Risk Factors
- No risk-factor text provided; excerpt references the December 31, 2024 Form 10-K
- No newly added quarterly risk identified in the provided excerpt
- No updated regulatory, legal, operational, competitive, or financial risk disclosed in the provided excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TriSalus Life Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.